---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-013720"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:24:12.525908+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024

## Summary
- Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
- Amendment to Certificate of Incorporation filed with Delaware Secretary of State on Nov 4, 2024, effective 12:01 a.m. ET on Nov 7, 2024.
- Common stock will trade on split-adjusted basis under new CUSIP 29273B 500 beginning Nov 7, 2024.
- Each issued share of common stock will be reclassified and converted into 1/35 of a share.
- No change to the par value of $0.0001 per share or the authorized number of shares.

## SEC filing metadata
- accession: 0001654954-24-013720
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424013720/0001654954-24-013720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424013720/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-013720
- JSON: https://secwatch.observer/filing/0001654954-24-013720.json
- Plain text: https://secwatch.observer/filing/0001654954-24-013720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.